EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 333 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... January 19, 2021 Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For... December 9, 2019 Breaking down the new standards for cancer care proposed by NHS... March 11, 2022 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Load more HOT NEWS Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective No Glucose? Pancreatic Cancer May Have a Ready Energy Alternative
